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Abstract
Osteoblasts are derived from bone marrow mesenchymal stem cell (BMSC) 
precursors, which differentiate into mature osteoblasts and mediate bone forma-
tion. This process is called osteoblastogenesis. A deficiency in osteoblastogenesis 
of BMSCs can result in bone-related diseases including osteoporosis. Thus, devel-
oping drugs for targeting osteoblastogenesis from BMSCs has become one of the 
therapeutic strategies for osteoporosis. In China, kidney-nourishing Chinese herbal 
drugs such as ER-Zhi-Wan have been believed to be potential for treating osteoporo-
sis through targeting osteoblast proliferation and differentiation. The key pathways 
for regulating osteoblastogenesis include canonical and noncanonical Wnt pathway, 
semaphorin-mediated pathway, and MAPK-mediated BMP2-Smad pathway. Some 
natural products have been confirmed to regulate more than one pathway and exert 
multi-target effect through the use of one compound or combined use of more than 
two compounds, such as wedelolactone and oleonuezhenide. In addition, tissue 
engineering provides a promising strategy in the field for targeting osteoblastogen-
esis. New types of biomaterials including hydroxyapatite (HAp) combined with 
Chinese medicine can exert enhanced effect on osteoblastogenesis and provide new 
therapy for treating osteoporosis.
Keywords: targets, osteoblastogenesis, traditional Chinese medicine, Wnt pathway, 
semaphorins, biomaterials
1. Introduction
The bone is a dynamic organ, capable of regenerating and remodeling throughout 
the lifetime. Bone remodeling is a process, which is mainly balanced by osteoblast-
mediated bone formation and osteoclast-mediated bone resorption. Bone marrow 
mesenchymal stem cells (BMSCs) are osteoprogenitors, which differentiates into 
maturated osteoblasts and mediated bone formation, therefore maintaining the 
balance of bone remodeling. The process of osteoblast proliferation and differentia-
tion from BMSCs is called osteoblastogenesis, which plays a key role for osteogenesis. 
A decrease in osteoblastogenesis of mesenchymal stem cells is observed to result in 
bone-related diseases, such as osteoporosis [1, 2]. Stimulation of proliferation and 
osteoblastogenesis from BMSCs becomes a therapeutic strategy for osteoporosis. A 
large number of factors have been implicated in regulating osteoblast differentia-
tion, such as the Wnt family [3, 4]. Canonical Wnt signaling is crucial for regulation 
of osteoblast development including osteoblast proliferation, differentiation, and 
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survival. Activation of the canonical Wnt signaling pathway involves recruitment 
of a complex including LRP5/6 and GSK3β, stabilization of β-catenin, regulation 
of transcription factors such as runx2, and activation of Wnt target genes [5]. This 
pathway is active in BMSCs, and therefore many signaling molecules are developed 
as drug targets such as GSK3β and LRP5/6. Noncanonical Wnt signaling pathway 
is mediated by Wnt5a, which activates downstream pathways including Wnt/Ca2+/
PKC, small GTPase Rho, and JNK pathways [6]. Consequently, transcription fac-
tors, such as AP1 family [7], are activated, and survival-related gene expression is 
induced. The anabolic agents, such as parathyroid hormone (PTH), are developed to 
treat osteoporosis through enhancing osteoblastogenesis. However, administration 
of PTH1–34 for a long time can increase bone resorption, resulting in bone neurosis 
[8]. Therefore, research is currently focusing on drugs that can simultaneously 
regulate bone resorption and bone formation and could thus develop a new class of 
dual-action therapeutic agents for osteoporosis [9, 10].
According to traditional Chinese medicine theory, “kidney-nourishing” herbal 
drugs are commonly believed to have the ability of nourishing bones and therefore 
are used to treat osteoporosis. Traditional Chinese herbs have the characteristics 
of multi-components and multi-target; thus the development of bifunctional 
agents from traditional Chinese herbs is promising. Many potential compounds 
isolated from “kidney-nourishing” herbal drugs have been found to enhance 
osteoblastogenesis [11]. We focus on a traditional Chinese prescription, called 
Er-Zhi-Wan, which consists of Ecliptae herba and Fructus Ligustri Lucidi. Extract of 
Er-Zhi-Wan has been reported to increase bone volume and enhance bone forma-
tion. We determine the components by using HPLC-MS method and screen the 
active compounds. Wedelolactone isolated from Ecliptae herba is firstly reported 
to inhibit osteoclastogenesis and simultaneously enhance osteoblastogenesis. In 
ovariectomized mice, administration of wedelolactone prevented ovariectomy-
induced bone loss by enhancing osteoblast activity and inhibiting osteoclast activ-
ity. At the molecular level, wedelolactone altered several key signaling pathways. 
Wedelolactone facilitated osteoblastogenesis through activation of Wnt/GSK3β/β-
catenin signaling pathway, which led to the activation of runx2 and the expression 
of downstream genes. Simultaneously, wedelolactone inhibited osteoclastogenesis 
through inhibition of RANKL/RANK/NF-κB pathway, resulting in suppression of 
c-Fos/NFATc1 activation and osteoclast marker gene expression. Although wede-
lolactone can treat osteoporosis with the characteristics of bifunctional activity, 
wedelolactone is not perfect. At the high dose, wedelolactone can trigger cytotoxic-
ity against BMSCs. Therefore, we propose that components from Fructus Ligustri 
Lucidi could alleviate wedelolactone-induced cytotoxicity, since it is believed that 
the synergy effect contributes for the improved therapeutic efficacies.
Several compounds from Fructus Ligustri Lucidi are determined to have the 
ability to enhancing osteoblastogenesis. Among them, oleonuezhenide is found 
to increase bone mineralization induced by wedelolactone. Additionally, high 
dose of wedelolactone-induced cytotoxicity in BMSCs was relieved by addition 
of oleonuezhenide, and these BMSCs protected by oleonuezhenide maintained 
osteoblastic activity. These data further confirm that oleonuezhenide enhances 
wedelolactone’s action on osteoblast differentiation and activity through Wnt/
CK2α/β-catenin pathway and prevents wedelolactone-induced cytotoxicity through 
Wnt5a/CK2α/ERK pathway, indicating that combination of different compounds 
generates multi-target effect. This might contribute for the efficacy for the mixture 
of different herbal drugs.
In addition to the development of new type of drugs for targeting osteoblas-
togenesis, tissue engineering provides a promising strategy in the field for osteo-
genesis from BMSCs, which aims to induce new, BMSC-driven, bone regeneration 
3Traditional Chinese Medicine Therapy for Targeting Osteoblastogenesis
DOI: http://dx.doi.org/10.5772/intechopen.82451
and has increased the possibility of engineering bone in vitro to treat bone defects 
particularly in vivo [12]. As alternatives polymeric biomaterials are applied in clini-
cal practice since the 1960s; their popularity is related to the ease of preparation of 
various products in complex shapes and a wide range of physical and mechanical 
properties. Hydroxyapatite (HAp) is a major mineral component of calcified tissues 
including bones. Synthetic HAp has been extensively used as an important mate-
rial for bone substitute, owing to its excellent osteoinductive properties. However, 
most HAp is considered to be weak in osteoinductive ability, which may impact the 
repair capacity for bone defects. Thus, the combined effect of HAp, growth factors, 
or osteoinductive agents such as natural products on osteoblastogenesis might be 
promising. We investigate the action of incorporation of wedelolactone and HAp 
nanoparticles with different shapes and sizes on osteoblastogenesis from BMSCs. 
First, HAps are constructed by a rodlike shape with different particle sizes. HAp-1 
combined with wedelolactone induced a higher ALP activity with different degrees, 
suggesting that combination of biomaterial and compounds contributes for osteo-
blastogenesis and thus can be used as therapeutic strategy for osteoporosis. Overall, 
this chapter will discuss recent findings regarding osteoblastogenesis and its related 
therapeutic strategies.
2. Osteoblastogenesis and its related therapies
2.1 The cellular and molecular mechanism of osteoblastogenesis
Osteoblasts arise from bone marrow mesenchymal stem cell (BMSC) precur-
sor, which differentiates into maturated osteoblasts and mediated bone formation. 
The maturated osteoblasts synthesize dense, cross-linked collagen and specialized 
proteins in much smaller quantities, including osteocalcin and osteopontin, which 
compose the organic matrix of bone. This organic matrix forms a strong and dense 
mineralized tissue—the mineralized matrix.
Along with osteoblasts, osteoclast breaks down bone matrix. The balance of 
bone formation and bone resorption maintained bone homeostasis [13]. However, 
the balance tends to be negative with age, particularly in postmenopausal women, 
often leading to a loss of bone serious enough to cause fractures, which is called 
osteoporosis. A decrease in osteoblastogenesis of mesenchymal stem cells can be 
observed in osteoporosis [2]. Reduced proliferation and osteoblastic differentiation 
of BMSCs were reported to associate with the reduction of healing capacity such as 
impairment of bone formation in osteoporotic patients. Therefore, stimulation of 
proliferation and osteoblastogenesis from BMSCs becomes a therapeutic strategy 
for osteoporosis.
There are several signaling pathways involved in osteoblastogenesis. BMP 
(bone morphogenetic protein) signaling is a fundamental pathway that mediates 
osteoblast differentiation [14]. BMP signaling is mediated through type I and 
type II BMP receptors. After binding to BMP ligands, BMP receptors formed a 
complex. This dynamic interaction leads to signal transduction through either 
Smads or mitogen-activated protein kinases (MAPKs) which further activates the 
transcription of specific target genes involved in osteoblastic differentiation and 
bone formation [15]. Several MAPKs have been identified, including extracellular 
signal-regulated kinases (ERKs), c-Jun N-terminal protein kinase (JNK), and p38 
MAPK. These three types of MAPKs are essential components of the signal trans-
duction machinery that occupy central positions in this differentiation process [16]. 
Following activation of MAPK signaling during this differentiation process, BMP2/
Smad signaling is activated.
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Canonical and noncanonical Wnt signaling pathways play key roles in the regu-
lation of osteoblast development including enhancement of osteoblast proliferation 
as well as differentiation [17]. The canonical Wnt/GSK3β/β-catenin signaling is a 
key pathway for regulating bone formation and contributing to osteoblastic differ-
entiation. Canonical Wnt pathway involves the formation of a complex consisting 
of Wnt1, 3a proteins, Frizzed, LRP5/6, and GSK3β. A crucial step in transducting 
the Wnt signal is to destroy the cytoplasmic GSK3β complex by inducing GSK3β 
phosphorylation and subsequently, inhibits β-catenin phosphorylation, thereby sta-
bilizing β-catenin. The accumulated β-catenin thus enters the nucleus and activates 
the expression of the Wnt target genes. These target genes include marker genes for 
osteoblastogenesis. Alkaline phosphatase is a membrane-anchored protein that is 
a characteristic marker expressed in large amounts at the apical (secretory) face of 
active osteoblasts. Other marker genes, including SP7 (which encodes osterix) and 
Bglap (encoding osteocalcin), were markedly increased in their expression during 
the osteogenic differentiation. Runx2 is the master osteogenic transcription fac-
tor that takes part in the process of osteoblast maturation. Runx2 is also found to 
transduce Wnt signaling for mediating osteogenic differentiation of BMSCs [18]. 
It can act as crosstalking regulator between Wnt signaling pathways and others 
that enhance osteoblastogenesis. The canonical Wnt signaling pathway is active in 
BMSCs, and therefore many signaling molecules are developed as drug targets such 
as GSK3β and LRP5/6.
Noncanonical Wnt signaling pathway is mediated by Wnt5a, which activates 
downstream pathways including Wnt/Ca2+/PKC, small GTPase Rho, and JNK path-
ways [19]. Noncanonical Wnt signaling pathway has been reported to regulate many 
cellular processes, including gene expression, cell proliferation, and apoptosis. Wnt5a 
can interact with Fz receptor and activates the cytoplasmic protein Dvl2 through 
casein kinase 2α (CK2α), which induces the activation of downstream molecules such 
as RhoA and ERK1/2. CK2 is a key regulator both in canonical and noncanonical Wnt 
signaling pathways [20, 21]. CK2α is its catalytic subunit. CK2α can induce nuclear 
translocation of β-catenin and thereby precluding degradation mediated by the 
proteasome. CK2α can also induce disheveled activation and therefore acts as a switch 
to define distinct branches of noncanonical Wnt signaling pathways. Although CK2α 
was developed as targets for embryogenesis, neuronal differentiation, and myogenic 
differentiation, the role of CK2α for osteoblastogenesis is still unclear.
Semaphorins are a family of cell-surface or soluble proteins that are able to 
regulate cell-cell interactions as well as cell differentiation, morphology, and func-
tion. In the mammalian system, 20 semaphorins have been identified and fall into 5 
classes (semaphorins 3–7) that are characterized by particular structural properties 
[22]. Among them, Sema3A play a key role in coupling of osteoblastogenesis and 
osteoclastogenesis. Sema3A is produced by osteoblasts and has been identified as a 
potent and direct inhibitor of osteoclast formation from osteoclast precursor cells. 
Distinct from other coupling factors, Sema3A promotes osteoblast differentiation 
from BMSCs (the precursor of osteoblasts), indicating a dual function role in which 
it inhibits osteoclastogenesis and enhances osteoblastogenesis [23]. The Sema3A 
signaling pathway is activated through binding with its cell-surface receptor 
composed of an Nrp1 and plexinA1 protein complex, which functions as a signal-
transducing subunit [24]. This complex induces different downstream signaling 
molecules in osteoclasts and osteoblasts, resulting in different regulatory effects 
on differentiation. Therefore, regulation of the Sema3A pathway in osteoclasts and 
osteoblasts would be promising for the bone remodeling balance and be helpful for 
the development of therapeutic agents.
In addition to Sema3A, several other semaphorins play a role in osteogenesis. 
They can be expressed on osteoclast or osteoblast. Sema3A and Sema3E are 
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produced from osteoblasts, while Sema4D and Sema6D are expressed by osteo-
clasts. Sema7A can be expressed in both osteoblasts and osteoclasts. The role 
of semaphorin family proteins in osteoblast and osteoclast is different [25–27]. 
Sema3E are produced from osteoblasts, while Sema4D and Sema6D are expressed 
by osteoclasts. Sema7A can be expressed in both osteoblasts and osteoclasts. The 
role of semaphorin family proteins in osteoblast and osteoclast is different. Sema7A 
is reported to be expressed in osteoblasts and promoted the osteoblast migration 
[28]. In addition to Sema7A, expression level of Sema3E from mouse osteoblasts was 
reported to be increased by PTH and 1, 25-(OH)2 D3 treatment [29]. The effects 
of semaphorins are mediated by plexins, a group of nine transmembrane recep-
tors that can be subdivided into four classes, plexins A–D. The semaphorin-plexin 
system has an important role in regulating bone cell function. Therefore, regulating 
the balance of semaphorin family protein levels and semaphorin-mediated signal-
ing pathway might balance bone remodeling through enhancing osteoblastogenesis 
and simultaneously inhibiting osteoclastogenesis.
2.2 Chinese herbal drugs for targeting osteoblastogenesis
2.2.1 Traditional Chinese medicine theory
Traditional Chinese medicine (TCM) is a style of traditional medicine built on a 
foundation of more than 2500 years of Chinese medical practice that includes vari-
ous forms of herbal medicine, acupuncture, massage (tui na), exercise (qigong), and 
dietary therapy [30] but recently is also influenced by modern Western medicine.
One of the basic theories of TCM is zàng-fǔ theory. The term zàng refers to the 
five entities, including the heart, liver, spleen, lung, and kidney, while fǔ refers 
to the six yang organs, including the small intestine, large intestine, gallbladder, 
urinary bladder, stomach, and Sānjiaō [31]. Among them, the kidney is considered 
to be related to bones. As distinct from the Western medical definition of kidneys, 
the TCM concept is more a way of describing a set of interrelated parts than an 
anatomical organ. The main functions of the kidney are to strengthen bones, 
dominate human growth and development, produce marrow to fill up the brain, 
etc. (Figure 1).
According to the Chinese medicine kidney theory, many kidney-nourishing 
herbal drugs can strengthen bones; therefore they are used for treatment of bone-
related diseases such as osteoporosis. Enhancement of osteoblastogenesis might be 
one of the mechanisms of action of these herbs. A famous Chinese doctor named 
Figure 1. 
The relationship of zàng-fǔ Chinese medicine theory and strengthen bones.
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Zhang Jie Bin (approximately 1563–1640) wrote “there are two kidneys, (kidney 
yin and yang), with the gate of vitality between them” (Figure 2). The difference 
between kidney yin and kidney yang on strengthening bones is still unclear, but the 
different mechanisms of action of kidney yin and yang on osteoblastogenesis might 
partially explain the difference.
2.2.2 Chinese herbal drugs that enhance osteoblastogenesis and/or inhibiting 
osteoclastogenesis
Many kidney-tonifying herbal drugs are found to regulate osteoblastogenesis. 
Some are kidney-yang herbal drugs, including Herba Epimedii, Taxus yunnanensis, 
Rhizoma Drynariae, etc. Some are kidney-yin herbal drugs, including Eclipta herbal 
and Fructus Ligustri Lucidi. Herba Epimedii is a commonly used Chinese medicine 
as “kidney yang” herbs for thousands of years. It contains active components such 
as flavonoids and phytosteroids. Total flavonoids of Herba Epimedii are suggested to 
enhance osteoblast proliferation and differentiation and to be potential candidates 
for treating osteoporosis [32]. It includes icariin, epimedin A, epimedin B, epimedin 
C, icariside II, icaritin, etc. Although icariin is a principal flavonoid glycoside in 
Herba Epimedii, icariside II and icaritin, two hydrolytic metabolites in vivo as well 
as present in Herba Epimedii, showed higher activity of osteoblast proliferation and 
differentiation [33, 34] (Table 1).
Ecliptae herba, also known as “Mo-Han-Lian,” is the aerial parts of 
Eclipta prostrata L. (Asteraceae), which have antiosteoporotic effect [45, 46]. 
Wedelolactone is a compound isolated from Ecliptae herba. Although ethyl acetate 
extract of Ecliptae herba and wedelolactone did not change BMSC proliferation, the 
extract and wedelolactone enhance BMSC differentiation toward osteoblasts. BMSC 
incubation with wedeloloactone results in an increase in the activity of alkaline 
phosphatase (ALP), a marker enzyme for maturated osteoblasts, in a dose-depen-
dent manner. Also, mineralization level and calcium deposits increased accordingly 
in response to wedelolactone. At the molecular level, wedelolactone directly inhib-
ited GSK3β activity and enhanced the phosphorylation of GSK3β and thereafter 
stimulated the nuclear translocation of β-catenin and runx2. The expression of 
osteoblastogenesis-related marker gene including osteorix, osteocalcin, and runx2 
was increased. In ovariectomized mice, administration of wedelolactone prevented 
ovariectomy-induced bone loss by enhancing osteoblast activity and promoting 
new bone formation [47].
Distinct with other osteogenic agent, such as PTH1–34, wedelolactone exert dual 
function role in enhancing osteoblastogenesis and simultaneously inhibiting osteo-
clastogenesis. For the anabolic agent, parathyroid hormone (PTH) a concomitant 
Figure 2. 
Different regulated roles of kidney yin and yang in osteoblastogenesis. Kidney yang and yin might alter 
osteoblast and osteoclast function and enhance osteoblastogenesis and inhibiting osteoclastogenesis.
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increase in bone resorption can be observed. These drawbacks of the current 
therapies might be attributed to one target for these drugs that fail to uncouple bone 
degradation and formation: they stimulate or inhibit both processes at the same 
time. Research is currently focusing on drugs that can simultaneously regulate bone 
resorption and bone formation. Wedelolactone might be potential for the develop-
ment of new class of drugs for treating osteoporosis. Further, the dual function of 
wedelolactone might be attributed to multi-target action on osteogenesis.
In addition to Wnt/GSK3β/β-catenin pathway activation by wedelolactone, we 
found that the semaphorin 3A pathway, as the upstream of Wnt/GSK3β/β-catenin 
pathway, was activated. Wedelolactone can increase mRNA expression of Sema3A 
in BMSCs and blocking Sema3A activity with its antibody reversed wedelolactone-
induced alkaline phosphatase activity in BMSCs. Further, wedelolactone enhanced 
binding of Sema3A with cell-surface receptors, including neuropilin (NRP)1 and 
plexinA1. In addition, nuclear accumulation of β-catenin, a transcription factor act-
ing downstream of wedelolactone-induced Sema3A signaling, was blocked by the 
Sema3A antibody. For the osteoclasts, a 9 day incubation fraction of conditioned 
media obtained from wedelolactone-treated bone marrow mesenchymal stem cell 
(BMSC) significantly inhibited tartrate-resistant acid phosphatase (TRAP) activity 
in RANKL-stimulated osteoclastic RAW264.7 cells. Conditioned media and wede-
lolactone promoted the formation of plexinA1-Nrp1, but conditioned media also 
caused these sequestration of the plexinA1-DNAX-activating protein12 (DAP12) 
complex and suppressed the phosphorylation of phospholipase C (PLC)γ2. These 
data suggest that wedelolactone promoted osteoblastogenesis through production 
of Sema3A, thus inducing the formation of a Sema3A-plexinA1-Nrp1 complex 
Compounds or extracts Herbal drugs or 
plants
Validation Refs.
Icarrin, icariside II, icaritin Herba Epimedii Enhance osteoblast proliferation 
and differentiation
[34]
Wedelolactone Ecliptae herba Promote osteoblast 
differentiation and bone 
formation
[35, 36]
Specnuezhenide, 
ligustroflavone, salidroside, 
and Gl3
Fructus Ligustrum 
lucidum
Stimulate osteoblast proliferation 
and bone formation by BMP2 and 
runx2 activation
[37, 38]
Puerariae radix extract Puerariae radix Play a role in osteoblastic bone 
formation; induces osteoblastic 
differentiation markers such as 
ALP, OCN, OPN, and Col I and 
mineralization in SaOS-2 cells
[39]
Tetrahydroxystilbene glucoside Fallopia multiflora Promote osteoblast 
differentiation
[40]
Total flavonoids Rhizoma Drynariae Enhance osteoblast activity 
through BMP2/Smad pathway
[41]
Aqueous extract Angelica sinensis Stimulate proliferation and ALP 
activity of OPC-1
[42]
Extract Salvia miltiorrhiza Stimulates ALP activity in 
MC3T3-E1 cells
[43]
Extract Astragalus
membranaceus
Promote new bone formation on 
periodontal defects in vivo
[44]
Table 1. 
Cellular and molecular targets for different herbal drugs with the ability of enhancing osteoblastogenesis.
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and β-catenin activation. In osteoclastic RAW264.7cells, wedelolactone inhibited 
osteoclastogenesis through sequestration of the plexinA1-DAP12 complex, induced 
the formation of plexinA1-Nrp1 complex, and suppressed PLCγ2 activation [48].
Semaphorin family proteins exert different roles in wedelolactone-enhance 
osteoblastogenesis and wedelolactone-inhibited osteoclastogenesis. In addition 
to Sema3A, osteogenic medium(OS)-reduced Sema7A mRNA expression and 
OS-enhanced Sema3E mRNA expression in BMSCs were reversed by wedelolactone, 
but OS-reduced Sema3B mRNA expression had no change. Although there is evidence 
of the role of Sema3B in bone remodeling [49], OS treatment decreased Sema3B 
mRNA expression. Wedelolactone and Sema3B antibody did not affect ALP activity. 
Sema3B is reported to inhibit the proliferation and induce apoptosis in various types 
of cancers. Whether Sema3B has a role in BMSC proliferation and apoptosis is needed 
to be further studied. Wedelolactone enhanced the binding of Sema7A with plexinC1 
and Beta1, but addition of Sema7A antibody partially blocked the binding triggered 
by wedelolactone. At the same time, addition of Sema4D antibody to wedelolactone-
treated osteoclastic RAW264.7 cells showed a more significant decrease in TRAP 
activity and bone resorption pit formation. Wedelolactone inhibited the production 
of Sema4D and formation of Sema4D-PlexinB1 complex. Overall, wedelolactone 
inhibited the production of Sema4D and formation of Sema4D-PlexinB1 complex in 
RAW264.7 cells, thereafter inhibiting osteoclastogenesis. At the same time, wedelo-
lactone enhanced osteoblastogenesis through promoting the production of Sema7A 
and Sema7A-PlexinC1-Beta1 complex formation in BMSCs. These results suggested 
that wedelolactone enhanced osteoblastogenesis but inhibited osteoclastogenesis 
through altering semaphorin family proteins [50].
BMP signaling pathways have a critical role in bone-formation process, and their 
effects can be mediated by Smad signaling. Among BMP family proteins, BMP2 has 
been reported to be essential for inducing bone formation [51]. Several studies have 
reported that MAPK signaling including JNK, ERK, and p38 pathways are involved 
in osteoblastogenesis [52]. p38 MAPK is required for osteoblast differentiation 
and induction of osteogenic marker genes. Also, p38 activation has been observed 
in lactoferrin-treated MC3T3-E1 cells. However, there is evidence that osteoblast 
differentiation is stimulated by activation of ERK and JNK, but not by activation of 
p38 MAPK [53]. Wedelolactone increased phosphorylation of extracellular signal-
regulated kinases (ERKs), c-Jun N-terminal protein kinase (JNK), and p38 in BMSCs. 
Phosphorylation of mitogen-activated protein kinases (MAPKs), ERK, and JNK 
started to increase on day 3 of treatment, and p38 phosphorylation was increased by 
day 6 of treatment. Expression of bone morphogenetic protein (BMP)2 mRNA and 
phosphorylation of Smad1/5/8 was enhanced after treatment of cells with wedelo-
lactone for 6 and 9 days. The addition of the JNK inhibitor SP600125, ERK inhibitor 
PD98059, and p38 inhibitor SB203580 suppressed wedelolactone-induced alkaline-
phosphatase activity and bone mineralization. Increased expression of BMP2 mRNA 
and Smad1/5/8 phosphorylation was blocked by SP600125 and PD98059, but not by 
SB203580. Our findings confirmed that wedelolactone enhanced osteoblastogenesis 
through induction of the JNK- and ERK-mediated BMP2-Smad1/5/8 pathway [54].
Wedelolactone is the derivation of coumarin, which can target estrogen recep-
tor and exert estrogenic activity. Wedelolactone also was found to be docked onto 
the crystal structure of GSK3β through electrostatic or hydrophobic interactions. 
Therefore, wedelolactone might exert multi-target effect and induce the signaling 
network for enhancing osteogenesis (Figure 3). However, wedelolactone at high 
dose has cytotoxicity against BMSC survival. Also, the concentration of wedelolac-
tone into the blood is lower, which limited the application for treatment of osteopo-
rosis in clinic. We suppose that other components combined with wedelolactone can 
exert synergetic effect.
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Er-Zhi-Wan is composed of Herba Ecliptae and Fructus Ligustri Lucidi, which 
is a famous traditional Chinese formulation firstly recorded in “Yi Bian” written in 
Ming Dynasty, which possesses the actions of tonifying the liver and kidney yin, 
nourishing body’s essential fluid, and arresting hemorrhage. Er-Zhi-Wan extracts 
have been reported to prevent osteoporosis and inhibit osteoclast differentiation 
[55]. Er-Zhi-Wan containing serum inhibited proliferation and differentiation of 
preosteoclastic RAW264.7 cells. Therefore, we screened the synergetic components 
from Fructus Ligustrum Lucidum.
Fructus Ligustrum Lucidum (FLL), also known as Nu-Zhen-Zi, is the fruit of 
Ligustrum lucidum Ait., which has been used in traditional Chinese medicine for 
over 1000 years to nourish the liver and the kidney and thereafter strengthen the 
bones. In modern research, FLL is reported to possess anticancer, antidiabetic, anti-
inflammatory, and heptoprotective effects. The crude FLL extract is reported to 
modulate the turnover of bone and the calcium balance in ovariectomized rats [56]. 
It also shows that ethanol extract improves calcium balance and bone metabolism in 
aged female rats through enhancing bone mineralization process [57]. The predomi-
nant components isolated from FLL include flavonoids, triterpenes, phenylethanoid 
glycosides such as salidroside, and secoiridoid glucosides such as specnuezhenide 
and ligustroflavone. Salidroside, specnuezhenide, and Gl3 are reported to increase 
osteoblast activity in osteoblast-like UMR106 cells. Aqueous extract of FLL acti-
vates ERα/β-mediated gene transcription, but the isolated compounds are inactive 
[58]. Salidroside is shown to promote the proliferation of BMSCs and increase the 
expression and secretion of stem cell factor (SCF) [59]. However, the cellular action 
of FLL and its compounds regulating bone metabolism is still unclear. In our study, 
FLL extract and five compounds from FLL were investigated to affect alkaline 
phosphatase (ALP) activity of bone marrow mesenchymal stem cells (BMSCs). 
FLL and its five components, including salidroside, specnuezhenide, nuezhenide 
G13, oleonuezhenide, and ligustroflavone, facilitated BMSC differentiation toward 
osteoblasts partially through BMP/LPR6/runx2 pathway.
Further, the combined effects of wedelolactone and various doses of compounds 
from Fructus Ligustri Lucidi, including oleonuezhenide, salidroside, and oleanolic 
acid, on osteoblastogenesis were evaluated. The combination of oleonuezhenide 
and wedelolactone was found to exert a synergistic effect on osteoblast differentia-
tion. Wedelolactone at 6 μM and oleonuezhenide at 9 μM enhanced osteoblast 
Figure 3. 
Involvement of signaling network in wedelolactone-induced osteoblastogenesis. Wedelolactone induced 
Sema7A, 3A-mediated signaling pathway, activated downstream of β-catenin nuclear translocation, and 
promoted BMP2/Smad1/5/8 pathway activation, resulting in enhancement of osteoblastogenesis.
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differentiation and bone mineralization. The enhanced effect was more potent 
when bone marrow mesenchymal stem cells were treated with a combination of 
wedelolactone and oleonuezhenide. Osteoblastogenesis-related marker genes 
including osteocalcin, runx2, and osteorix were upregulated in the presence of 6 μM 
wedelolactone and 9 μM oleonuezhenide. At the molecular level, oleonuezhenide 
did not affect GSK3β phosphorylation induced by wedelolactone but elevated casein 
kinase 2α (CK2α) expression, resulting in β-catenin and runx2 nuclear transloca-
tion. The addition of 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine 
(DMAT), a CK2α inhibitor, blocked oleonuezhenide-induced alkaline phosphatase 
(ALP) activity, and simultaneously suppressed β-catenin nuclear accumulation, 
induced by treatment with a combination of oleonuezhenide and wedelolactone. In 
addition, 30 μM wedelolactone-induced cytotoxicity in bone marrow mesenchymal 
stem cells was relieved by 9 μM oleonuezhenide. These bone marrow mesenchymal 
stem cells were protected by oleonuezhenide and maintained osteoblastic activity. 
Oleonuezhenide increased Wnt5a and CK2α expression. Wedelolactone-reduced 
extracellular signal-regulated kinase (ERK) phosphorylation was reversed by 
oleonuezhenide. However, the addition of DMAT reduced ERK phosphorylation 
induced by oleonuezhenide. Taken together, these data demonstrate that 10 μM 
oleonuezhenide enhanced the effects of 6 μM wedelolactone on osteoblastogenesis, 
by GSK3β- and CK2α-mediated β-catenin activation. Thus, wedelolactone-induced 
cytotoxicity was prevented through CK2α-mediated ERK activation. This com-
bined effect of wedelolactone and oleonuezhenide on osteoblastogenesis may be 
contributed to understanding the efficiency of Er-Zhi-Wan on curing bone-related 
diseases, such as osteoporosis.
2.3 Combined therapy by using biomaterials and drugs
Tissue engineering provides a promising strategy in the field for osteoblasto-
genesis from BMSCs, which aims to induce new, BMSC-driven, bone regeneration 
and has increased the possibility of engineering bone in vitro to treat bone defects 
particularly in vivo [60–62]. As alternatives polymeric biomaterials are applied in 
clinical practice since the 1960s. Their popularity is related to the ease of prepa-
ration of various products in complex shapes, their moderate price, and a wide 
range of physical and mechanical properties. Biocomposite scaffolds are gener-
ally used for bone tissue engineering to act as a temporary matrix and provide 
a suitable environment for cell proliferation, differentiation, and extracellular 
matrix (ECM) deposition until it is restored by new natural tissue over the desired 
time. Various biomaterials are designed to engineer bone tissue. The bone tissue 
engineering scaffolds possess non-cytotoxicity, a high surface to volume ratio, 
abundant porosity for the transport of nutrients and regulatory factors, intercon-
nectivity of pores for neovascularization at the site of new tissue regeneration, 
and osteoconductive and osteoinductive properties. Most of these material 
properties are satisfied by poly(L-lactic acid)-co-poly (ε-caprolactone) (PLACL), 
which is a copolymer of PCL and PLLA and was found to be potential synthetic 
polymer for bone regeneration therapy. Osteoblasts cultured on biocompatible 
poly(L-lactic acid)-co-poly (ε-caprolactone)-silk fibroin-hydroxyapatite-hyal-
uronic acid (PLACL-SF-HAp-HA) showed a significantly higher level of prolifera-
tion and increased osteogenic differentiation and mineralization [63]. Promising 
polymeric biomaterials however often do not fulfill the necessary requirements 
for the production of suitable bone implants. One of the challenges to overcome 
is the proliferation of cells on the implant surface [64] which could be achieved 
by mimicking the natural 3D bone structure with a composite of organic polymer 
and inorganic components.
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Hydroxyapatite (HAp) is a major mineral component of calcified tissues includ-
ing bones. Synthetic HAp has been extensively used as an important material for 
bone substitute, owing to its excellent osteoinductive properties [65]. Synthetic HAp 
[Ca10(PO4) 6(OH)2) has been extensively used as an implant material for bone 
substitute, owing to its excellent osteoinductive properties. Calcium phosphate bio-
materials (HAp-TCP) with appropriate 3D geometry are able to bind and concentrate 
endogenous bone morphogenetic proteins in circulation, may become osteoinductive, 
and can be effective carriers for bone cells. Different characteristics and sizes of HAp 
are developed to be generally used for bone tissue engineering, which acts as a tempo-
rary matrix and provides a suitable environment for cell proliferation, differentiation, 
and extracellular matrix (ECM) deposition. However, HAp is considered to be weak in 
osteoinductive ability, which may impact the repair capacity for bone defects. Growth 
factors play an important role in the process of bone formation; some scaffolds have 
been developed as delivery carriers for growth factors and showed great bone repair 
ability. However, considering the high production cost and limited active period, the 
clinical application of exogenous growth factors is restricted. We proposed that natural 
products combined with HAp might have enhanced effect on osteoblastogenesis. Three 
kinds of HAps constructed by a rodlike shape with particle size of 25 nm (HAp-1), 
37 nm (HAp-2), and 33 nm (HAp-3) did not affect BMSC survival but induced activity 
of alkaline phosphatase (ALP), a marker enzyme for osteoblastogenesis. The rodlike 
HAp might have distinct properties for osteoblast differentiation [66]. Additionally, 
particle size is a very important influencing factor on activity of HAp samples. The 
smallest particle has the best activity might be due to its easier contact of the target 
in the cell. The O-H groups abundantly located in the surface of HAp-1 crystal might 
facilitate the hydrogen bond interaction between the HAp-1 and the protein of the cell, 
which is in accordance with cell activity data. The structure and activity relationship 
analyses give us some instruction to design new HAp samples with smaller size and 
more hydroxyl group to improve activity.
Interestingly, the combination of HAp-1 and wedelolactone exhibited a higher 
and more prolong time for ALP activity, indicating that HAp-1 and wedelolactone 
exerted synergetic effect on ALP activity. Recent studies have demonstrated that due 
to the excellent specific surface area, micro-/nano-hybrid structured HAp (micro-
nano HAp) granules could be applied as carriers of drug delivery systems to enhance 
osteogenic ability [67]. HAp-1 treatment resulted in a more significant increase 
in the number of ALP staining-positive BMSCs and maintained an extended time 
for the increased number of ALP staining-positive BMSCs. The extended time for 
enhanced ALP activity in the presence of HAp-1 and wedelolactone indicates that 
HAp-1 might have the ability of carrying wedelolactone and subsequently sustained 
release of wedelolactone from the HAp-1. HAp-1 combined with wedelolactone 
induced a higher ALP activity for a longer time than HAp-2 and HAp-3 and also 
increased the bone mineralization level. Osteoblastogenesis-related marker gene 
expression including osteorix, osteocalcin, and runx2 were increased after BMSCs 
were treated with HAp-1. In conclusion, HAp, which is a major mineral component 
of calcified tissues including bones, with different sizes generated different effects 
on osteoblastogenesis. HAp-1 combined with wedelolactone exerted an enhanced 
effect on osteoblastic differentiation, mineralization, and osteoblastogenesis-related 
marker gene expression, which has potential for treating osteoporosis.
3. Conclusion
Targeting osteoblastogenesis has become a promising therapeutic strategy for 
treatment of osteoporosis. Several pathways including canonical and noncanonical 
Osteogenesis and Bone Regeneration
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Wnt pathway, semaphorin pathway, and BMP/Smad pathway play a critical role 
in regulating osteoblastogenesis. Regulating the biological network for enhancing 
osteoblastogenesis and simultaneously inhibiting osteoclastogenesis might develop 
new type of multi-target drug for treating osteoporosis. The kidney-nourishing 
Chinese herbal drugs have the potential since these herbs contain many components 
and thus exert synergetic effect. The multi-target mechanism of Er-Zhi-Wan, a 
prescription record since Ming Dynasty in China, is confirmed by study of com-
bined effect of wedelolactone and oleonuezhenide. Further study of these herbs as 
well as screening the active components might find novel potential drugs. Further, 
the development of tissue engineering biomaterials and combination with Chinese 
herbal drugs might generate the superior therapeutic effect.
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